Related Experiment Video
Updated: Nov 3, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.2K
Bimekizumab for Moderate-to-Severe Plaque Psoriasis
1University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada.
Skin Therapy Letter
|June 2, 2021
Summary
Bimekizumab effectively treats moderate-to-severe plaque psoriasis by inhibiting interleukin-17A and IL-17F. This study discusses its safety and efficacy in patients with this chronic inflammatory skin condition.
Area of Science:
- Immunodermatology
- Inflammatory skin diseases
- Biologics in dermatology
Background:
- Psoriasis is a prevalent immune-mediated skin disease affecting 2% of the population.
- It is linked to significant comorbidities and driven by inflammatory pathways.
- Interleukin-17 (IL-17) signaling is a key factor in psoriasis pathogenesis.
Purpose of the Study:
- To evaluate the safety and efficacy of bimekizumab for moderate-to-severe plaque psoriasis.
- To highlight bimekizumab's mechanism of action as a dual inhibitor of IL-17A and IL-17F.
Main Methods:
- Review of clinical trial data on bimekizumab in plaque psoriasis.
- Assessment of safety profiles and efficacy endpoints (e.g., skin clearance).
Main Results:
- Bimekizumab demonstrated significant efficacy in achieving skin clearance in patients with moderate-to-severe plaque psoriasis.
- The safety profile of bimekizumab was consistent with its mechanism of action.
Conclusions:
- Bimekizumab is a promising therapeutic option for moderate-to-severe plaque psoriasis.
- Its dual inhibition of IL-17A and IL-17F offers a targeted approach to managing this inflammatory condition.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
258
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
258
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
299
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
299
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
272
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
272
01:29Inflammatory Bowel Disease IV: Pharmacological Management
254
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
254
01:29Drugs for Treatment of Ulcerative Colitis in IBD
284
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
284
01:21Drugs for Treatment of Constipation-Predominant IBS
426
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
426